Quanterix unveils Content Innovation Engine at AACR 2026
The Content Innovation Engine integrates Akoya's spatial biology platform and Quanterix's immunoassay infrastructure to unlock cancer biology and accelerate clinical application
20 Apr 2026
Quanterix Corporation is to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration of Akoya Biosciences' spatial biology platform and Quanterix's ultra-sensitive, quantitative immunoassay development from the SIMOA® technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a systematic, biology-first approach to revealing more from every tissue section.
It is supported by the end-to-end capabilities spatial biology needs to advance beyond discovery: world-class spatial instrumentation, and the assay design and reagent formulation expertise, quality systems, and manufacturing scale to support measurements that meet the requirements of translational and clinical applications.
"Spatial biology has fundamentally changed how we see cancer,” said Everett Cunningham, President and CEO of Quanterix. “Akoya built a platform that gave researchers an entirely new way to study it. What Quanterix brings is the assay expertise, quality systems, and scale to carry that science further, into translational settings, into the clinic, into decisions that affect patients. The Content Innovation Engine is the first expression of what that combination makes possible."
Quanterix will also introduce a new IO60 Spike-In Module extending biological coverage into two high-priority areas: checkpoint therapy markers spanning PD-1/PD-L1, CTLA-4, and next-generation blockade; and tertiary lymphoid structure (TLS) markers, an emerging correlate of durable immunotherapy response.
In addition, the PhenoCode Molecular Barcoding Kit will be showcased AACR. Built on a new PhenoCode 2.0 chemistry, the kit enables researchers to barcode virtually any antibody of their choice with exceptional reliability and yield. Existing panels can be expanded into immuno-oncology, neuroscience, and beyond without adding complexity to the workflow. Early access begins May 2026.
The Accelerator Service Lab will present two new ADC lung cancer panels for PhenoImager HT. Building on the ADC breast cancer panel debut at AACR 2025, both panels are available as a fully managed service.
Finally, Quanterix's growing spatial biology community will also be represented at AACR 2026, with 25+ posters from customers and collaborators presenting data generated on PhenoCycler-Fusion and PhenoImager HT across a range of cancer indications.